Anthony P. Bihl III has taken the helm as the Interim CEO of Bioventus Inc. since April 2023. He isn't new to the scene—previously, he served as CEO of Bioventus LLC from 2013 to 2020, so he knows the company...

Anthony P. Bihl III has taken the helm as the Interim CEO of Bioventus Inc. since April 2023. He isn't new to the scene—previously, he served as CEO of Bioventus LLC from 2013 to 2020, so he knows the company well. Anthony’s career spans a range of leadership roles in the medical field, including stints at Siemens and Bayer HealthCare. With a Bachelor of Science in Business Administration from Pennsylvania State University, he’s got a solid foundation in business and operations. Anthony also holds positions on several boards, like Spectral Medical and Sonendo, showcasing his expertise beyond Bioventus. Under his guidance, Bioventus is navigating a key transition with a deeper focus on innovative solutions in healthcare. It’s an exciting time in the company as Anthony brings in his extensive experience to lead the team forward.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Bioventus CEOs

B

Anthony P. Bihl III

CEO of Bioventus

Education

Bachelor of Science in Business Administration from Pennsylvania State University

Field of Expertise

Business & Management

Sector of Economy

Healthcare

CEO of Bioventus for

2 years 2 months (Apr 2023 - Present)

Previous Experience

CEO of Diagnostics Division of Siemens Medical Solutions

Rivals

Competitors/colleagues of Anthony P. Bihl III

Holdings

See how much did Anthony P. Bihl III make over time.

Anthony P. Bihl III has shown active engagement with Bioventus Inc. through a series of notable stock transactions. His insider trading activity peaked in mid-2024, with the highest transaction recorded at approximately $1.70 million in September. This reflects a steady...

Anthony P. Bihl III has shown active engagement with Bioventus Inc. through a series of notable stock transactions. His insider trading activity peaked in mid-2024, with the highest transaction recorded at approximately $1.70 million in September. This reflects a steady increase in trading value month over month, indicating potential confidence in the company's stock performance. Initially, in May 2023, his trades were valued at around $335.31K, demonstrating a significant growth trajectory in his holdings as he remained engaged with the company through its transitions. As of his latest trades, upwards adjustments suggest he is strategically managing his portfolio, aligning with Bioventus's ongoing developments.

Mar 17, 2025

B

shares

BVS @ $9.80

Insider Trading

See recent insider trades of Anthony P. Bihl III.

SONX

200,000 shares

SONX

Sep 17, 2024

Received

BVS

$165.08K

BVS at $4.14/share

Aug 18, 2023

Purchase

SONX

25,316 shares

SONX

Jun 16, 2023

Received

BVS

$290.99K

BVS at $2.33/share

May 23, 2023

Purchase

SONX

34,682 shares

SONX

Jun 29, 2022

Received

SONX

$58.00K

SONX at $2.90/share

May 17, 2022

Purchase

SONX

$42.75K

SONX at $2.85/share

May 16, 2022

Purchase

SONX

$40.05K

SONX at $2.67/share

May 13, 2022

Purchase

SONX

$192.00K

SONX at $12.00/share

Nov 2, 2021

Purchase

Compensation History

See how much did Anthony P. Bihl III make over time.

In 2023, Anthony P. Bihl III's total compensation as Interim CEO of Bioventus Inc. was reported at $582,360. His salary comprised the bulk of this at $559,649. Additionally, he received a performance-based bonus of $74, which was granted in cash, reflecting specific performance metrics such as Global Revenue and Quality. Notably, no stock awards vested for him this year; his stock options will fully vest early in 2024 due to his departure from the company. This structure aligns with Bioventus's philosophy, designed to incentivize high performance and ensure the company's leadership remains motivated toward achieving its goals. Besides this, the compensation package includes various benefits, notably matching contributions in a 401(k) plan and life insurance premiums.

Year

2023

Total Compensation

$584.36K

Salary

$559.65K

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies, focusing on performance-based incentives.

Bonus

$74.00

Board Justification

The bonus for 2023 was based on performance metrics and was paid in cash as he was no longer an employee at the time of grant.

Other

$24.64K

Board Justification

Other compensation includes matching 401(k) contributions and life insurance premiums paid by the company.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock awards vested in 2023 as Mr. Bihl's stock options and RSUs were accelerated and vested on January 9, 2024, after his termination.

Performance Metrics

The performance metrics for the bonus included Global Revenue, Adjusted Global EBITDA, and Quality.

Other Bioventus CEOs

Here are other CEOs of Bioventus

Kenneth Reali

Ex-CEO of Bioventus

April 2020 - April 2023